Influence of amyloid and APOE on cognitive performance in a late middle-aged cohort

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Introduction: Few studies have examined the effects of amyloid and apolipoprotein E (APOE) genotype on cognition among middle-aged individuals. Methods: We included 464 cognitively normal, test-naïve, participants with Pittsburgh compound B positron emission tomography amyloid imaging, mean age of 62.7 (range, 51-71 years), enrolled in the Mayo Clinic Study of Aging. Participants completed multiple cognitive assessments, including a standard neuropsychological battery and the CogState computerized battery, over 30 months of follow-up. Linear mixed models were used to examine the effects of amyloid and APOE genotype on baseline cognition and cognitive decline. Results: Elevated amyloid was not associated with tests of episodic memory but did predict declines on tests of executive function. APOE genotype was not associated with cognition. Among APOE e(open)4 noncarriers, higher amyloid was predictive of decline on tests of executive function and on one episodic memory test. Discussion: Elevated amyloidosis and APOE genotype do not appear to exert a dramatic influence on cognition in middle age.

Original languageEnglish (US)
JournalAlzheimer's and Dementia
DOIs
StateAccepted/In press - 2015

Fingerprint

Apolipoproteins E
Amyloid
Cognition
Genotype
Episodic Memory
Executive Function
Amyloidosis
Positron-Emission Tomography
Linear Models

Keywords

  • Alzheimer's disease
  • Amyloid
  • APOE
  • Cognitive aging
  • Cohort studies
  • PET

ASJC Scopus subject areas

  • Clinical Neurology
  • Developmental Neuroscience
  • Cellular and Molecular Neuroscience
  • Psychiatry and Mental health
  • Geriatrics and Gerontology
  • Epidemiology
  • Health Policy

Cite this

@article{daa71ff4e0544510af2c89d3d954d525,
title = "Influence of amyloid and APOE on cognitive performance in a late middle-aged cohort",
abstract = "Introduction: Few studies have examined the effects of amyloid and apolipoprotein E (APOE) genotype on cognition among middle-aged individuals. Methods: We included 464 cognitively normal, test-na{\"i}ve, participants with Pittsburgh compound B positron emission tomography amyloid imaging, mean age of 62.7 (range, 51-71 years), enrolled in the Mayo Clinic Study of Aging. Participants completed multiple cognitive assessments, including a standard neuropsychological battery and the CogState computerized battery, over 30 months of follow-up. Linear mixed models were used to examine the effects of amyloid and APOE genotype on baseline cognition and cognitive decline. Results: Elevated amyloid was not associated with tests of episodic memory but did predict declines on tests of executive function. APOE genotype was not associated with cognition. Among APOE e(open)4 noncarriers, higher amyloid was predictive of decline on tests of executive function and on one episodic memory test. Discussion: Elevated amyloidosis and APOE genotype do not appear to exert a dramatic influence on cognition in middle age.",
keywords = "Alzheimer's disease, Amyloid, APOE, Cognitive aging, Cohort studies, PET",
author = "Mielke, {Michelle M} and Machulda, {Mary Margaret} and Hagen, {Clinton E.} and Christianson, {Teresa J.} and Roberts, {Rosebud O} and Knopman, {David S} and Vemuri, {Prashanthi D} and Val Lowe and Kremers, {Walter K} and Jack, {Clifford R Jr.} and Petersen, {Ronald Carl}",
year = "2015",
doi = "10.1016/j.jalz.2015.09.010",
language = "English (US)",
journal = "Alzheimer's and Dementia",
issn = "1552-5260",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Influence of amyloid and APOE on cognitive performance in a late middle-aged cohort

AU - Mielke, Michelle M

AU - Machulda, Mary Margaret

AU - Hagen, Clinton E.

AU - Christianson, Teresa J.

AU - Roberts, Rosebud O

AU - Knopman, David S

AU - Vemuri, Prashanthi D

AU - Lowe, Val

AU - Kremers, Walter K

AU - Jack, Clifford R Jr.

AU - Petersen, Ronald Carl

PY - 2015

Y1 - 2015

N2 - Introduction: Few studies have examined the effects of amyloid and apolipoprotein E (APOE) genotype on cognition among middle-aged individuals. Methods: We included 464 cognitively normal, test-naïve, participants with Pittsburgh compound B positron emission tomography amyloid imaging, mean age of 62.7 (range, 51-71 years), enrolled in the Mayo Clinic Study of Aging. Participants completed multiple cognitive assessments, including a standard neuropsychological battery and the CogState computerized battery, over 30 months of follow-up. Linear mixed models were used to examine the effects of amyloid and APOE genotype on baseline cognition and cognitive decline. Results: Elevated amyloid was not associated with tests of episodic memory but did predict declines on tests of executive function. APOE genotype was not associated with cognition. Among APOE e(open)4 noncarriers, higher amyloid was predictive of decline on tests of executive function and on one episodic memory test. Discussion: Elevated amyloidosis and APOE genotype do not appear to exert a dramatic influence on cognition in middle age.

AB - Introduction: Few studies have examined the effects of amyloid and apolipoprotein E (APOE) genotype on cognition among middle-aged individuals. Methods: We included 464 cognitively normal, test-naïve, participants with Pittsburgh compound B positron emission tomography amyloid imaging, mean age of 62.7 (range, 51-71 years), enrolled in the Mayo Clinic Study of Aging. Participants completed multiple cognitive assessments, including a standard neuropsychological battery and the CogState computerized battery, over 30 months of follow-up. Linear mixed models were used to examine the effects of amyloid and APOE genotype on baseline cognition and cognitive decline. Results: Elevated amyloid was not associated with tests of episodic memory but did predict declines on tests of executive function. APOE genotype was not associated with cognition. Among APOE e(open)4 noncarriers, higher amyloid was predictive of decline on tests of executive function and on one episodic memory test. Discussion: Elevated amyloidosis and APOE genotype do not appear to exert a dramatic influence on cognition in middle age.

KW - Alzheimer's disease

KW - Amyloid

KW - APOE

KW - Cognitive aging

KW - Cohort studies

KW - PET

UR - http://www.scopus.com/inward/record.url?scp=84954288922&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84954288922&partnerID=8YFLogxK

U2 - 10.1016/j.jalz.2015.09.010

DO - 10.1016/j.jalz.2015.09.010

M3 - Article

C2 - 26602629

AN - SCOPUS:84954288922

JO - Alzheimer's and Dementia

JF - Alzheimer's and Dementia

SN - 1552-5260

ER -